First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations-Reference-Cited by-同舟云学术

First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations

Published:2024-01 Issue: Volume:196 Page:113458
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Janku Filip^ORCID,Kim Tae Min^ORCID,Iyer Gopakumar^ORCID,Spreafico Anna,Elez Elena^ORCID,de Jonge Maja,Yamamoto Noboru^ORCID,van der Wekken Anthonie J.,Ascierto Paolo Antonio,Maur Michela,Marmé Frederik^ORCID,Kiladjian Jean-Jacques^ORCID,Basu Sumit^ORCID,Baffert Fabienne,Buigues Amparo,Chen Chi,Cooke Vesselina,Giorgetti Elisa,Kim Jaeyeon,McCarthy Fiona,Moschetta Michele,Dummer Reinhard^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Progress on Ras/MAPK signaling research and targeting in blood and solid cancers;Dillon;Cancers (Basel),2021

2. Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants;Giri;Curr Opin Gastroenterol,2017

3. Characterization of KRAS mutation subtypes in non-small cell lung cancer;Judd;Mol Cancer Ther,2021

4. The current understanding on the impact of KRAS on colorectal cancer;Meng;Biomed Pharm,2021

5. Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy;ElNaggar;Gynecol Oncol,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting RAF dimers in RAS mutant tumors: From biology to clinic;Acta Pharmaceutica Sinica B;2024-05

2. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?;The Cancer Journal;2024-03

3. Combination of the Novel Raf Dimer Inhibitor Brimarafenib with the Mek Inhibitor Mirdametinib is Effective Against Nras Mutant Melanoma;2024